TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the Stifel 2015 Healthcare Conference and the Jefferies Autumn 2015 Global Healthcare Conference. The company will host a conference call and webcast on November 17 to provide a corporate update and discuss third quarter 2015 financial results.
| Conference Call & Webcast | |
| Tuesday, November 17 @ 8:30am Eastern | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 56489875 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through December 1, 2015 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 56489875 |
| Stifel 2015 Healthcare Conference | |
| Date: | Tuesday, November 17 |
| Time: | 11:00am ET |
| Location: | Lotte New York Palace, New York, NY |
| Presenter: | Dr. Yaron Daniely, CEO |
| Webcast: | www.veracast.com/webcasts/stifel/healthcare2015/91105605087.cfm |
| Jefferies Autumn 2015 Global Healthcare Conference | |
| Date: | Thursday, November 19 |
| Time: | 12:40pm GMT (7:40 am ET) |
| Location: | The Mayfair Hotel, London, UK |
| Presenter: | Dr. Yaron Daniely, CEO |
| Webcast: | http://wsw.com/webcast/jeff92/adhd/index.aspx |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.